Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

KLRS

Kalaris Therapeutics Inc

Feb 09 • 04:00PM ET

9.05

+0.71 8.51 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI SURI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.40	Insider Own	81.09%	Shs Outstand	18.70M	Perf Week	-0.66%
Market Cap	151.48M	Forward P/E	-	EPS next Y	-2.14	Insider Trans	0.00%	Shs Float	3.54M	Perf Month	9.56%
Enterprise Value	76.02M	PEG	-	EPS next Q	-0.59	Inst Own	8.25%	Short Float	24.51%	Perf Quarter	91.33%
Income	-51.71M	P/S	-	EPS this Y	69.51%	Inst Trans	1.21%	Short Ratio	6.72	Perf Half Y	238.95%
Sales	0.00M	P/B	4.04	EPS next Y	36.78%	ROA	-50.77%	Short Interest	0.87M	Perf YTD	7.23%
Book/sh	2.24	P/C	1.97	EPS next 5Y	48.05%	ROE	-63.45%	52W High	12.90 -29.84%	Perf Year	-9.50%
Cash/sh	4.60	P/FCF	-	EPS past 3/5Y	42.89% -6.86%	ROIC	-120.16%	52W Low	2.14 322.90%	Perf 3Y	-94.08%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.11% 8.62%	Perf 5Y	-99.12%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	63.31%	Oper. Margin	-	ATR (14)	0.73	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.89	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.38	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	12.89	EPS Q/Q	22.66%	SMA20	-2.11%	Beta	-0.10	Target Price	18.60
Payout	-	Debt/Eq	0.04	Sales Q/Q	-	SMA50	5.95%	Rel Volume	0.43	Prev Close	8.34
Employees	6	LT Debt/Eq	0.03	Earnings	Nov 12 BMO	SMA200	76.90%	Avg Volume	129.10K	Price	9.05
IPO	Jul 30, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	-4.58% -	Trades		Volume	57,114	Change	8.51%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-23-25	Initiated	Chardan Capital Markets	Buy	$19
Nov-03-25	Initiated	Citizens JMP	Mkt Outperform	$20
Sep-03-25	Initiated	Raymond James	Strong Buy	$23
Jul-23-25	Resumed	Piper Sandler	Neutral	$3
May-07-25	Initiated	Leerink Partners	Outperform	$20
Apr-08-25	Initiated	William Blair	Outperform

Jan-28-26 04:05PM	Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting (GlobeNewswire)
Dec-17-25 05:59PM	Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement (GlobeNewswire) +20.32%
04:01PM	Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naive Neovascular AMD (GlobeNewswire)
Nov-24-25 08:00AM	Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference (Newsfile) -7.99%
Nov-12-25 08:00AM	Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
07:30AM	Loading…
Nov-03-25 07:30AM	Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer (GlobeNewswire)
Oct-30-25 08:00AM	Kalaris to Present at Stifel 2025 Annual Healthcare Conference (GlobeNewswire)
Sep-15-25 03:26PM	UPDATE - Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration (GlobeNewswire)
08:00AM	Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration (GlobeNewswire)
Sep-01-25 12:00PM	Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-13-25 08:00AM	Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -8.43%
Jun-02-25 08:00AM	Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference (GlobeNewswire)
May-23-25 11:03AM	Kalaris to Participate at Stifel Ophthalmology Forum (GlobeNewswire)
May-14-25 08:00AM	Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-04-25 08:00AM	Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee (GlobeNewswire)
04:21PM	Loading…
Mar-18-25 04:21PM	Kalaris Announces Closing of Merger with AlloVir (GlobeNewswire) +16.92%

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company is headquartered in Berkeley Heights, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hagen Brett R	Chief Accounting Officer	Mar 26 '25	Sale	8.97	907	8,135	1,925	Mar 27 07:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KLRS

Kalaris Therapeutics Inc

Upgrade your FINVIZ experience